Computed tomography scans do not improve the predictive power of 1996 national cancer institute-sponsored working group chronic lymphocytic leukemia response criteria

Journal of Clinical Oncology

Volumn 25, Issue 35, 2007, Pages 5624-5629

  Blum, Kristie A ^a   Young, Donn ^a   Broering, Sarah ^a   Lucas, Margaret S ^a   Fischer, Beth ^a   Lin, Thomas S ^a   Grever, Michael R ^a   Byrd, John C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; BONE MARROW EXAMINATION; CANCER CENTER; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; TREATMENT PLANNING;

ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NATIONAL CANCER INSTITUTE (U.S.); PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 37649012888     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.12.1152     Document Type: Article

References (21)

1. Reis L, Harkins D, Krapcho M, et al: SEER Cancer Statistics Review, 1975-2003. Bethesda, MD, National Cancer Institute, 2005
2. Chanan-Khan A, Miller KC, Musial L, et al: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 24:5343-5349, 2006
3. Cherukuri A, Kadel E, Lee SH, et al: Human antagonistic anti-CD40 antibody, CHIR-12.12, inhibits CD40-mediated survival of chronic lymphocytic leukemia B cells leading to cellular apoptosis. Proc Am Soc Hematol 106:832, 2005 (abstr 2965)
4. Kater AP, Dicker F, Fukuda T, et al: CD40-activation of chronic lymphocytic leukemia cells induces latent sensitivity to Fas/TRAIL-mediated apoptosis via a P53-independent, C-Abl-dependent pathway. Proc Am Soc Hematol 104:101, 2004 (abstr 342)
5. Tong X, Georgakis GV, Li L, et al: In vitro activity of a novel fully human anti-CD40 antibody CHIR-12.12 in chronic lymphocytic leukemia: Blockade of CD40 activation and induction of ADCC. Proc Am Soc Hematol 104:686, 2004 (abstr 2504)
6. Byrd JC, O'Brien S, Flinn I, et al: Safety and efficacy results from a phase I trial of single-agent lumiliximab (anti-CD23 antibody) for chronic lymphocytic leukemia. Proc Am Soc Hematol 104:686, 2004 (abstr 2503)
7. Byrd JC, Lin TS, Dalton JT, et al: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 109:399-404, 2007
8. Cheson B, Bennett J, Grever M, et al: National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
9. Byrd JC, Peterson BL, Morrison VA, et al: Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101:6-14, 2003
10. Byrd JC, Rai K, Peterson BL, et al: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 105:49-53, 2005
11. Keating MJ, O'Brien S, Albitar M, et al: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23:4079-4088, 2005
12. Montillo M, Tedeschi A, Miqueleiz S, et al: Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 24:2337-2342, 2006
13. Wierda W, O'Brien S, Wen S, et al: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 23:4070-4078, 2005
14. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
15. Harris NL, Jaffe ES, Diebold J, et al: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849, 1999
16. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
17. Muntañola A, Bosch F, Arguis P, et al: Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia. J Clin Oncol 25:1576-1580, 2007
18. Maslak P, Caravelli J, Chanan-Khan AA: "Complete" remission in chronic lymphocytic leukemia (CLL) is strongly affected by the use of CT scanning: Results from a prospective randomized trial of fludarabine plus cyclophosphamide (Flu/Cy) with or without genasense (Oblimersen) in patients with relapsed or refractory disease. Proc Am Soc Hematol 108:802, 2006 (abstr 2834)
19. Bosch F, Muntanola A, Ferrer A, et al: Computed tomography (CT) predicts response duration in patients with chronic lymphocytic leukemia (CLL) in complete response (CR) by conventional, NCI-working group, criteria. Proc Am Soc Hematol 108: 802, 2006 (abstr 2835)
20. O'Brien SM, Kantarjian HM, Cortes J, et al: Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414-1420, 2001
21. Eichhorst BF, Busch R, Hopfinger G, et al: Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107:885-891, 2006